Literature DB >> 29183075

Chemical Composition and Labeling of Substances Marketed as Selective Androgen Receptor Modulators and Sold via the Internet.

Ryan M Van Wagoner1, Amy Eichner2, Shalender Bhasin3, Patricia A Deuster4, Daniel Eichner1.   

Abstract

Importance: Recent reports have described the increasing use of nonsteroidal selective androgen receptor modulators, which have not been approved by the US Food and Drug Administration (FDA), to enhance appearance and performance. The composition and purity of such products is not known. Objective: To determine the chemical identity and the amounts of ingredients in dietary supplements and products marketed and sold through the internet as selective androgen receptor modulators and compare the analyzed contents with product labels. Design and Setting: Web-based searches were performed from February 18, 2016, to March 25, 2016, using the Google search engine on the Chrome and Internet Explorer web browsers to identify suppliers selling selective androgen receptor modulators. The products were purchased and the identities of the compounds and their amounts were determined from April to August 2016 using chain-of-custody and World Anti-Doping Association-approved analytical procedures. Analytical findings were compared against the label information. Exposures: Products marketed and sold as selective androgen receptor modulators. Main Outcomes and Measures: Chemical identities and the amount of ingredients in each product marketed and sold as selective androgen receptor modulators.
Results: Among 44 products marketed and sold as selective androgen receptor modulators, only 23 (52%) contained 1 or more selective androgen receptor modulators (Ostarine, LGD-4033, or Andarine). An additional 17 products (39%) contained another unapproved drug, including the growth hormone secretagogue ibutamoren, the peroxisome proliferator-activated receptor-δ agonist GW501516, and the Rev-ErbA agonist SR9009. Of the 44 tested products, no active compound was detected in 4 (9%) and substances not listed on the label were contained in 11 (25%). In only 18 of the 44 products (41%), the amount of active compound in the product matched that listed on the label. The amount of the compounds listed on the label differed substantially from that found by analysis in 26 of 44 products (59%). Conclusions and Relevance: In this limited investigation involving chemical analyses of 44 products marketed as selective androgen receptor modulators and sold via the internet, most products contained unapproved drugs and substances. Only 52% contained selective androgen receptor modulators and many were inaccurately labeled.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29183075      PMCID: PMC5820696          DOI: 10.1001/jama.2017.17069

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  14 in total

1.  Characterization of a non-approved selective androgen receptor modulator drug candidate sold via the Internet and identification of in vitro generated phase-I metabolites for human sports drug testing.

Authors:  Mario Thevis; Andreas Lagojda; Dirk Kuehne; Andreas Thomas; Josef Dib; Annelie Hansson; Mikael Hedeland; Ulf Bondesson; Tina Wigger; Uwe Karst; Wilhelm Schänzer
Journal:  Rapid Commun Mass Spectrom       Date:  2015-06-15       Impact factor: 2.419

Review 2.  Adverse health consequences of performance-enhancing drugs: an Endocrine Society scientific statement.

Authors:  Harrison G Pope; Ruth I Wood; Alan Rogol; Fred Nyberg; Larry Bowers; Shalender Bhasin
Journal:  Endocr Rev       Date:  2013-12-17       Impact factor: 19.871

Review 3.  Food and Drug Administration Drug Approval Process: A History and Overview.

Authors:  Christopher Ty Williams
Journal:  Nurs Clin North Am       Date:  2016-01-13       Impact factor: 1.208

4.  Performance-enhancing drugs on the web: a growing public-health issue.

Authors:  Brian P Brennan; Gen Kanayama; Harrison G Pope
Journal:  Am J Addict       Date:  2013-02-01

5.  The safety, pharmacokinetics, and effects of LGD-4033, a novel nonsteroidal oral, selective androgen receptor modulator, in healthy young men.

Authors:  Shehzad Basaria; Lauren Collins; E Lichar Dillon; Katie Orwoll; Thomas W Storer; Renee Miciek; Jagadish Ulloor; Anqi Zhang; Richard Eder; Heather Zientek; Gilad Gordon; Syed Kazmi; Melinda Sheffield-Moore; Shalender Bhasin
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2012-03-28       Impact factor: 6.053

6.  MK-0677 (ibutamoren mesylate) for the treatment of patients recovering from hip fracture: a multicenter, randomized, placebo-controlled phase IIb study.

Authors:  Abraham Adunsky; Julie Chandler; Norman Heyden; Jeannine Lutkiewicz; Boyd B Scott; Yuliya Berd; Nancy Liu; Dimitris A Papanicolaou
Journal:  Arch Gerontol Geriatr       Date:  2010-11-09       Impact factor: 3.250

Review 7.  Roles of Peroxisome Proliferator-Activated Receptor β/δ in skeletal muscle physiology.

Authors:  Ravikumar Manickam; Walter Wahli
Journal:  Biochimie       Date:  2016-12-02       Impact factor: 4.079

8.  Anabolic steroids detected in bodybuilding dietary supplements - a significant risk to public health.

Authors:  V Abbate; A T Kicman; M Evans-Brown; J McVeigh; D A Cowan; C Wilson; S J Coles; C J Walker
Journal:  Drug Test Anal       Date:  2014-10-06       Impact factor: 3.345

9.  Heavy Testosterone Use Among Bodybuilders: An Uncommon Cohort of Illicit Substance Users.

Authors:  Mary E Westerman; Cameron M Charchenko; Matthew J Ziegelmann; George C Bailey; Todd B Nippoldt; Landon Trost
Journal:  Mayo Clin Proc       Date:  2016-01-05       Impact factor: 7.616

10.  Regulation of circadian behaviour and metabolism by synthetic REV-ERB agonists.

Authors:  Laura A Solt; Yongjun Wang; Subhashis Banerjee; Travis Hughes; Douglas J Kojetin; Thomas Lundasen; Youseung Shin; Jin Liu; Michael D Cameron; Romain Noel; Seung-Hee Yoo; Joseph S Takahashi; Andrew A Butler; Theodore M Kamenecka; Thomas P Burris
Journal:  Nature       Date:  2012-03-29       Impact factor: 49.962

View more
  8 in total

1.  Omitted Conflict of Interest Disclosures.

Authors: 
Journal:  JAMA       Date:  2018-02-20       Impact factor: 56.272

2.  Could Overt Diabetes Be Triggered by Abuse of Selective Androgen Receptor Modulators and Growth Hormone Secretagogues? A Case Report and Review of the Literature.

Authors:  Richard Sotorník; Roguel Suissa; Jean-Luc Ardilouze
Journal:  Clin Diabetes       Date:  2022

3.  Performance-Enhancing Substance Use and Sexual Risk Behaviors among U.S. Men: Results from a Prospective Cohort Study.

Authors:  Kyle T Ganson; Dylan B Jackson; Alexander Testa; Pamela M Murnane; Jason M Nagata
Journal:  J Sex Res       Date:  2021-12-03

4.  Selective androgen receptor modulators activate the canonical prostate cancer androgen receptor program and repress cancer growth.

Authors:  Michael D Nyquist; Lisa S Ang; Alexandra Corella; Ilsa M Coleman; Michael P Meers; Anthony J Christiani; Cordell Pierce; Derek H Janssens; Hannah E Meade; Arnab Bose; Lauren Brady; Timothy Howard; Navonil De Sarkar; Sander B Frank; Ruth F Dumpit; James T Dalton; Eva Corey; Stephen R Plymate; Michael C Haffner; Elahe A Mostaghel; Peter S Nelson
Journal:  J Clin Invest       Date:  2021-05-17       Impact factor: 14.808

Review 5.  Harm Reduction in Male Patients Actively Using Anabolic Androgenic Steroids (AAS) and Performance-Enhancing Drugs (PEDs): a Review.

Authors:  Alex K Bonnecaze; Thomas O'Connor; Cynthia A Burns
Journal:  J Gen Intern Med       Date:  2021-05-04       Impact factor: 6.473

Review 6.  Selective androgen receptor modulators: the future of androgen therapy?

Authors:  Andrew R Christiansen; Larry I Lipshultz; James M Hotaling; Alexander W Pastuszak
Journal:  Transl Androl Urol       Date:  2020-03

7.  Decreased expression of Rev-Erbα in the epileptic foci of temporal lobe epilepsy and activation of Rev-Erbα have anti-inflammatory and neuroprotective effects in the pilocarpine model.

Authors:  Jiong Yue; Jiaojiang He; Yujia Wei; Kaifeng Shen; Kefu Wu; Xiaolin Yang; Shiyong Liu; Chunqing Zhang; Hui Yang
Journal:  J Neuroinflammation       Date:  2020-01-31       Impact factor: 8.322

8.  Associations between legal performance-enhancing substance use and future cardiovascular disease risk factors in young adults: A prospective cohort study.

Authors:  Jason M Nagata; Kyle T Ganson; Mitchell L Cunningham; Deborah Mitchison; Jason M Lavender; Aaron J Blashill; Holly C Gooding; Stuart B Murray
Journal:  PLoS One       Date:  2020-12-15       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.